PARIS–(BUSINESS WIRE)–Regulatory News: CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to fulfill an unmet medical need by providing a therapeutic alternative to people suffering from end-stage biventricular heart failure, informs its […]
Tag: Carmat
CARMAT Reports Its FY 2021 Financial Results and Confirms Its 2022 Prospects
Revenue of €2.2 million corresponding to the first sales of Aeson® hearts Aeson® implants expected to resume in October 2022 Available financial resources providing financial visibility until July 2022 Company actively exploring financing options beyond H1 2022 CARMAT (FR0010907956, ALCAR), […]
CARMAT Anticipates Implants of Its Aeson® Artificial Heart to Resume in October 2022
PARIS–(BUSINESS WIRE)–Regulatory News: CARMAT (Paris:ALCAR): Videoconference in English with Stéphane Piat at 8 pm CET today. To participate, please register by clicking on this link CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming […]
CARMAT Announces the Completion of Its Investigations on Previously Identified Quality Issues
PARIS–(BUSINESS WIRE)–Regulatory News: CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to fulfill an unmet medical need by providing a therapeutic alternative to people suffering from end-stage biventricular heart failure, announces the […]
CARMAT Announces the First Implant of Its Aeson® Total Artificial Heart in the Netherlands
The implant took place at the University Medical Centre Utrecht, The Netherlands November 15, 2021 01:00 AM Eastern Standard Time PARIS–(BUSINESS WIRE)–Regulatory News: CARMAT (Paris:ALCAR) (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming […]
CARMAT Announces the Publication of an Article on the Aeson®’s Autoregulation System in the ASAIO Journal
Results from 10 patients enrolled in the PIVOTAL study show that autoregulation enables an appropriate and immediate adaptation of cardiac output to patients’ needs CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming […]
CARMAT Announces First Implant of Its Total Artificial Heart in a Female Recipient
The procedure was performed at UofL Health – Jewish Hospital by University of Louisville physicians in the first cohort of the U.S. Early Feasibility Study PARIS–(BUSINESS WIRE)–Regulatory News: CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced […]
CARMAT Receives Final Approval From the Patient Protection Committee for the Use of the Commercial Version of the Aeson® Heart in the EFICAS Study in France
PARIS–(BUSINESS WIRE)–Regulatory News: CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to fulfill an unmet medical need by providing a therapeutic alternative to people suffering from end-stage biventricular heart failure, today announces […]
CARMAT Reports Its 2021 Half-year Results and Issues an Update on Its Latest Progress and Main Strategic Objectives
6 Aeson® artificial hearts marketed to date Enrollment of the first cohort of 3 patients in the EFS1 in the USA finalized Cash position of €58 million at June 30, 2021, covering the Company’s activities through to mid-2022 Videoconference with Stéphane […]
CARMAT Announces a New Commercial Implant of Its Aeson® Artificial Heart at University Medical Center Schleswig-holstein in Kiel, Germany
PARIS–(BUSINESS WIRE)–Regulatory News: CARMAT (FR0010907956, ALCAR) (Paris:ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from end-stage biventricular heart failure, today announces the third implant of its […]